As of 2025-12-28, the EV/EBITDA ratio of AnaptysBio Inc (ANAB) is -16.06. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. AnaptysBio's latest enterprise value is 1,609.28 mil USD. AnaptysBio's TTM EBITDA according to its financial statements is -100.23 mil USD. Dividing these 2 quantities gives us the above AnaptysBio EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.2x - 15.6x | 15.3x |
| Forward P/E multiples | 22.2x - 23.1x | 22.3x |
| Fair Price | (88.45) - (64.56) | (76.07) |
| Upside | -276.5% - -228.9% | -251.8% |
| Date | EV/EBITDA |
| 2025-12-24 | -16.03 |
| 2025-12-23 | -16.04 |
| 2025-12-22 | -16.12 |
| 2025-12-19 | -15.77 |
| 2025-12-18 | -15.35 |
| 2025-12-17 | -14.84 |
| 2025-12-16 | -14.65 |
| 2025-12-15 | -14.80 |
| 2025-12-12 | -14.63 |
| 2025-12-11 | -14.86 |
| 2025-12-10 | -14.63 |
| 2025-12-09 | -14.31 |
| 2025-12-08 | -14.51 |
| 2025-12-05 | -14.47 |
| 2025-12-04 | -14.18 |
| 2025-12-03 | -14.30 |
| 2025-12-02 | -13.51 |
| 2025-12-01 | -13.63 |
| 2025-11-28 | -13.72 |
| 2025-11-26 | -13.86 |
| 2025-11-25 | -13.68 |
| 2025-11-24 | -13.80 |
| 2025-11-21 | -13.16 |
| 2025-11-20 | -12.62 |
| 2025-11-19 | -12.44 |
| 2025-11-18 | -12.44 |
| 2025-11-17 | -11.82 |
| 2025-11-14 | -11.56 |
| 2025-11-13 | -11.40 |
| 2025-11-12 | -11.36 |
| 2025-11-11 | -11.49 |
| 2025-11-10 | -11.60 |
| 2025-11-07 | -13.17 |
| 2025-11-06 | -12.77 |
| 2025-11-05 | -12.16 |
| 2025-11-04 | -11.81 |
| 2025-11-03 | -12.17 |
| 2025-10-31 | -12.32 |
| 2025-10-30 | -12.29 |
| 2025-10-29 | -12.19 |
| 2025-10-28 | -12.20 |
| 2025-10-27 | -12.21 |
| 2025-10-24 | -11.90 |
| 2025-10-23 | -11.61 |
| 2025-10-22 | -11.51 |
| 2025-10-21 | -11.64 |
| 2025-10-20 | -11.96 |
| 2025-10-17 | -11.78 |
| 2025-10-16 | -11.72 |
| 2025-10-15 | -11.69 |